PerkinElmer

Search Results for 'IVIS'

Products & Services (20)
Filters:

Filters :

Show results for
Product Type
  • Accessories (4)
  • Consumables (5)
  • Instruments (8)
  • Reagents (1)
  • Software and Informatics (2)
Imaging Modality
  • Bioluminenscence (1)
  • microCT Imaging (1)
  • Optical Imaging (8)
Length
  • 51-100 (8)
Product Brand Name
  • IVIS (9)
  • XenoLight (1)

1-12 of 20 Products & Services

Sort by

  • IVIS Spectrum In Vivo Imaging System

    IVIS Spectrum In Vivo Imaging System

    The IVIS® Spectrum in vivo imaging system combines 2D optical and 3D optical tomography in one platform. The system uses leading optical technology for preclinical imaging research and development ideal for non-invasive longitudinal monitoring of disease progression, cell trafficking and gene expression patterns in living animals.
  • IVIS Spectrum In Vivo Imaging System

    IVIS SpectrumBL High-Throughput In Vivo Optical Imaging System

    The IVIS® SpectrumBL is an advanced high-throughput 2D and 3D optical imaging system designed to improve quantitative outcomes of bioluminescent, chemiluminescent and Cerenkov in vivo imaging.
  • IVIS SpectrumCT 2D/3D Optical/CT In Vivo Imaging System

    IVIS SpectrumCT In Vivo Imaging System

    The IVIS® SpectumCT preclinical in vivo imaging system expands upon the versatility of the IVIS Spectrum by offering 2D and 3D imaging capabilities but includes integrated low-dose microCT ideal for longitudinal studies. The system provides researchers with greater insights into complex biological systems by enabling simultaneous molecular and anatomical non-invasive imaging in animal models.
  • IVIS Lumina HT High Throughput Benchtop 2D Optical Imaging System

    IVIS Lumina LT In Vivo Imaging System

    The IVIS® Lumina LT Series III pre-clinical in vivo imaging system offers the industries most sensitive benchtop platform at an entry level price.
  • IVIS Lumina HT High Throughput Benchtop 2D Optical Imaging System

    IVIS Lumina III In Vivo Imaging System

    The IVIS® Lumina Series III brings together years of leading optical imaging technologies into one easy to use and exquisitely sensitive bench-top system.
  • IVIS Lumina XRMS 2D Optical Imaging System with Integrated X-ray

    IVIS Lumina XRMS In Vivo Imaging System

    Industry leading Fluorescence, Bioluminescence and X-Ray Imaging - All-In-One benchtop instrument! The IVIS® Lumina XRMS (x-ray multi-species optical imaging system) adds to the versatility of the IVIS Lumina XR by offering the flexibility to image large animals up to 500 grams with precise optical and X-Ray overlay.
  • IVIS Lumina S5 high throughput, high sensitivity optical in vivo imaging system

    IVIS Lumina S5 Imaging System

    The IVIS® Lumina S5 high-throughput 2D optical imaging system combines high-sensitivity bioluminescence and fluorescence in a benchtop format. With an expanded 5 mouse field of view for 2D optical imaging plus our unique line of accessories to accelerate setup and labeling, it has never been easier or faster to get robust data—and answers—on anatomical and molecular aspects of disease.
  • IVIS Lumina X5 in vivo imaging system

    IVIS Lumina X5 Imaging System

    High-Sensitivity Optical Meets High-Resolution X-ray

    The IVIS® Lumina X5 high-throughput 2D optical imaging system combines high-sensitivity bioluminescence and fluorescence with high-resolution x-ray into a compact system that fits on your benchtop. With an expanded 5 mouse field of view for 2D optical imaging plus our unique line of accessories to accelerate setup and labeling, it has never been easier or faster to get robust data—and answers—on anatomical and molecular aspects of disease.
  • XNC?-2 Mouse Nose Cones

    XNC-2 Mouse Nose Cones, set of 10

    These transparent glass nose cones are low luminescent and low fluorescent. They are for use with the XGI-8 Anesthesia System and 5-port anesthesia system manifold.
    List Price : 596.00 USD
  • XIC-5 IVIS Induction Chamber

    This induction chamber can anesthetize up to 5 adult mice or 2 rats simultaneously. It is used for use with the IVIS® XGI-8 Gas Anesthesia system.
    List Price : 1836.00 USD
  • Syringe Injection System (IVIS Lumina Series III systems and Spectrum CT)

    This syringe injection system enables users to image while simultaneously inject compounds into mice. The system is used for use with Lumina Systems or SpectrumCT systems.
    List Price : 10900.00 USD
  • Mice imaging using IVIS Lumina and Living Image Software

    Living Image Software – IVIS Lumina Series

    Advanced Acquisition and Analysis Tools for IVIS® Lumina Imaging Systems

    Living Image® advanced in vivo imaging software designed for the IVIS Lumina platform simplifies even the most complex image acquisition and analysis of 2D bioluminescent and fluorescent probes. With streamlined interfaces and workflows for longitudinal analysis of 2D data including co-registration with X-ray in applicable IVIS Lumina systems, Living Image in vivo imaging software sets the industry standard for ease of use and flexibility.
  • Jump to:
Business Insights (7)
Filters:

1-7 of 7 Business Insights

Sort by

  • Application Note

    Imaging Hepatocellular Liver Injury using NIR-labeled Annexin V

    Drug induced liver injury (DILI) is a major reason for late stage termination of drug discovery research projects, highlighting the importance of early integration of liver safety assessment in the drug development process. A technical approach for in vivo toxicology determination was developed using Acetaminophen (APAP), a commonly used over-the-counter analgesic and antipyretic drug, to induce acute hepatocellular liver injury.

  • Application Note

    Multiplex 2D Imaging of NIR Molecular Imaging Agents on the IVIS SpectrumCT and FMT 4000

    Epifluorescence (2D) imaging of superficially implanted mouse tumor xenograft models offers a fast and simple method for assessing tumor progression or response to therapy. This approach for tumor assessment requires the use of near infrared (NIR) imaging agents specific for different aspects of tumor biology, and this Application Note highlights the ease and utility of multiplex NIR fluorescence imaging to characterize the complex biology within tumors growing in a living mouse.

  • Application Note

    Vascular Imaging Probes For Oncology and Inflammation Using the IVIS Spectrum

    Optical-based in vivo imaging of vascular changes and vascular leak is an emerging modality for studying altered physiology in a variety of different cancers and inflammatory states. A number of fluorescent imaging probes that circulate with the blood, but have no target selectivity, have been used to detect tumor leakiness as an indication of abnormal tumor vasculature. Inflammation is also characterized by distinct vascular changes, including vasodilation and increased vascular permeability, which are induced by the actions of various inflammatory mediators. This process is essential for facilitating access for appropriate cells, cytokines, and other factors to tissue sites in need of healing or protection from infection. This application note investigates the use of three fluorescent imaging probes, to detect and monitor vascular leak and inflammation in preclinical mouse breast cancer models.

  • Application Note

    Stem Cell Research and Regenerative Medicine

    With the potential to treat a wide range of disease, from organ damage to congenital defects, stem cell research and tissue engineering form the underlying basis of regenerative medicine. Significant advances in the science of skin regeneration, for example, have now made it possible to develop and grow artificial skin grafts in a lab for treatment of burn victims. Other therapeutic applications include the use of stem cells to treat and repair central nervous system diseases such as ischemia and cerebral palsy, cardiovascular diseases, as well as autoimmune diseases including type I diabetes.

  • Poster

    Molecular imaging of tumor energy metabolism as an early indicator of anti-cancer drug efficacy in small animal models

    Targeted cancer therapy aims to block key signaling pathways that are critical for tumor cell growth and survival. The blockage eventually results in cell death via apoptosis and tumor growth suppression. Encouraged by the success in clinical development, many academic and pharmaceutical researcher are in active pursuit of the improvement of next generation targeted anti-cancer drugs. As a result, many new chemical and biological entities are emerging from initial screening of in vitro, in vitro and/or in silico selection processes. From the perspective of drug development, it poses a great challenge on the next stage of in vivo validation and demands a robust, accurate, and efficient method for assessment of these candidates in living animal models.

  • Poster

    Combined efficacy & toxicity imaging following acute 5-FU treatment of HT-29 tumor xenografts

    Cancer chemotherapy can produce severe side effects such as suppression of immune function and damage to heart muscle, gastrointestinal tract, and liver. If serious enough, tissue injury can be a major reason for late stage termination of drug discovery research projects, so it is becoming more important to integrate safety/toxicology assessments earlier in the drug development process. There are a variety of traditional serum markers, tailored mechanistically to specific tissues, however there are no current non-invasive assessment tools that are capable of looking broadly at in situ biological changes in target and non-target tissue induced by chemical insult.

  • Poster

    In vivo fluorescent imaging of tumor bombesin and transferrin receptor expression as early indicators of sorafenib efficacy in small animal models

    Targeted cancer therapy aims to block key signaling pathways that are critical for tumor cell growth and survival. The blockage eventually results in cell death via apoptosis and eventual tumor growth suppression. This strategy has proven to be quite effective, and the FDA has approved several targeted therapeutics in the past decade. Encouraged by the success in clinical development, many academic and pharmaceutical researchers are in active pursuit of improved next generation targeted anti-cancer drugs. As a result, many new chemical and biological entities are emerging from initial screening of in vitro, in vitro and/or in silico selection processes. From the perspective of drug development, it poses a great challenge for the next stage of in vivo validation and demands a robust, accurate, and efficient method for assessment of these candidates in living animal models.